top of page
VentureHaven-1688941584_edited.jpg

IDENTIFYING & INVESTING IN TRANSFORMATIVE 
HEALTHCARE COMPANIES

Venture Haven Investing in Transformative Healthcare Companies 2.jpg
circles-GettyImages-1477756487.png

About Us

Our goal is to identify and partner with innovative companies, advance science, improve the lives of patients, and generate attractive returns.

Unique Partnership

Brings together complementary strengths of investment and market expertise in Kishen Mehta, a Portfolio Manager of two healthcare/biotech focused Strategies; and operational, clinical, and commercial expertise in Dr. Vlad Coric, Founder, Board Chairman, and CEO of Biohaven (NYSE: BHVN).

Differentiated Approach

Support company growth throughout the financial and operational lifecycle while also leveraging deep scientific and market expertise to advance meaningful technologies in the fastest manner possible.

 

Our goal is to build authentic partnerships by providing ongoing guidance as companies build and grow.

Robust Opportunity Set

Identify and invest in the creation or growth of healthcare companies of all stages that are generating impactful solutions for unmet needs.

 

Healthcare is a complicated but transformative sector with durable secular growth and innovation. VentureHaven believes that the investment opportunity is profound and will continue to be robust.

Our Experience

The VentureHaven team has experience in almost all areas of healthcare and will seek to leverage an extensive network of relationships and deep fundamental work to identify attractive opportunities.

Mr. Mehta and Dr. Coric are supported by a multifaceted investment team that has advanced medical and scientific experience.

 

The investment team members bring together a diverse set of experiences ranging from startups to commercial stage public companies and have demonstrated a strong track record of success together.

VentureHaven-1494028631.jpg

VentureHaven is looking to invest in an era where powerful synergies between novel disease insights, unprecedented depth in genomics, unrivaled delivery methods and new drug technologies can dramatically improve patient's lives.

Our Team

circles-GettyImages-1477756487_edited.png

Contact Us

We'd love to hear from you

Thanks for submitting!

© 2024 VentureHaven | All Rights Reserved.

This website contains information regarding the prospective strategy and organization of VentureHaven Capital Partners, LP (“VentureHaven” or the “Firm”) a new investment adviser expected to be formed and registered with the SEC. VentureHaven has not commenced operations, and anticipates a launch in 2024. It is possible that VentureHaven will launch later than expected or not at all. The information presented on this website does not constitute investment advice or recommendations and does not constitute an offer to sell or a solicitation of an offer to buy an interest in any entity advised by VentureHaven and may not be relied upon in connection with any offer or sale of any interests or shares. Any information contained on this website is meant to be informational only and not meant to be indicative of any portfolio of any entity advised by VentureHaven. There can be no assurance that any of the professionals listed on this website will remain with the Firm or that past performance of such professionals serves as an indicator of his or her performance or success.

bottom of page